Insilico Medicine uses AI to reduce drug development time in China. The company's fastest programme reached candidate nomination in nine months.
Key facts
- •Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year.
- •The company's fastest programme reached candidate nomination in nine months.
- •Conventional approaches usually take about four-and-a-half years to reach the same stage.
- •Insilico has generated 31 preclinical candidates since 2021.
- •Thirteen programmes have received investigational new drug clearances.
- •The company has announced a proposed strategic alliance with Taiwan-based Bora Pharmaceuticals that could exceed $2.5 billion.
Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China. The company's fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months. Conventional approaches usually take about four-and-a-half years to reach the same stage.
By the numbers
AI-Driven Drug Development
Insilico uses generative AI to identify biological targets, design potential drug molecules, and assess which compounds should advance to laboratory testing. The company said its programmes typically reach preclinical-candidate nomination within 12 to 18 months after researchers synthesise and test between 60 and 200 molecules.
Research and Development
Insilico has generated 31 preclinical candidates since 2021. Thirteen programmes have received investigational new drug clearances, allowing them to advance towards human studies. The company conducts AI research in Montreal and Abu Dhabi, while much of its experimental validation and laboratory scale-up work takes place in China.
China's Research Infrastructure
CEO Alex Zhavoronkov attributed part of the shorter development cycle to China's research infrastructure, operating costs, and regulatory environment. China has expanded beyond manufacturing generic drug ingredients and now plays a larger role in developing new medicines. International drugmakers also work with Chinese laboratories, contract research organisations, clinical-trial centres, and biotechnology companies.
Partnerships and Trials
Insilico has entered research and development agreements with pharmaceutical companies including Eli Lilly and Japan's Takeda. The company announced a proposed strategic alliance with Taiwan-based Bora Pharmaceuticals that could exceed $2.5 billion. Insilico also announced a Phase III trial of Rentosertib, an oral drug being studied for idiopathic pulmonary fibrosis.
Timeline
- 2021Insilico started generating preclinical candidates
- 2024Analysis of AI-native biotechnology pipelines reported Phase I success rates of between 80% and 90%
- 2025China introduced a 30-working-day review pathway for eligible Class I innovative-drug clinical-trial applications
- July 2026Insilico announced a Phase III trial of Rentosertib
- August 2026Enrolment for the Phase III trial of Rentosertib was expected to begin
- October 2029Primary completion of the Phase III trial of Rentosertib is estimated
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Artificial Intelligence News.
